Ipamorelin 10 mg

Ipamorelin is a synthetic pentapeptide consisting of 5 modified amino acids and engineered as a selective agonist of the growth-hormone secretagogue receptor (GHS-R1a, the ghrelin receptor). It is classified as a GHS-R research peptide developed for investigation of ghrelin-receptor signaling research and somatotropic-axis research models.

Through selective engagement of GHS-R1a on pituitary somatotrophs and peripheral tissues, Ipamorelin is investigated as a tool compound for studying ghrelin-receptor (GHS-R) research, Gq/phospholipase-C signaling, and selective somatotropic-axis modulation that does not appreciably engage adjacent endocrine pathways (ACTH, cortisol, prolactin) in laboratory research models. This receptor selectivity profile distinguishes Ipamorelin from earlier non-selective GHS research peptides.

Ipamorelin is actively investigated across several research domains, including GHS-R1a receptor pharmacology, somatotropic-axis research models, ghrelin-receptor signaling research in gastrointestinal-motility laboratory models, and selective receptor-level investigation. Published characterization established Ipamorelin as the first selective GHS-R agonist with a selectivity profile for somatotropic-axis signaling comparable to that observed with GHRH receptor engagement (Raun et al., 1998, European Journal of Endocrinology). Research combining Ipamorelin with GHRH-receptor agonists has investigated receptor-coupled signaling interactions in controlled laboratory models.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

The growth-hormone secretagogue receptor (GHS-R1a) was identified as the endogenous receptor for ghrelin, a 28-amino-acid acylated peptide involved in somatotropic-axis signaling and metabolic research. Early non-selective GHS research peptides (GHRP-6, GHRP-2, hexarelin) engaged GHS-R1a but also produced collateral activity at other endocrine pathways, limiting their utility as receptor-selective research tools.

Ipamorelin was developed by Novo Nordisk researchers as a five-residue scaffold designed to selectively engage GHS-R1a while minimizing collateral receptor activity. Structural studies and receptor-binding research established the pentapeptide as a high-affinity, high-selectivity GHS-R agonist suitable for laboratory investigation of receptor-mediated signaling.

This positioning at the intersection of ghrelin-receptor signaling research, selective GPCR pharmacology, and somatotropic-axis research models has made Ipamorelin a peptide of considerable interest in laboratory investigations of GHS-R1a biology and downstream growth-hormone-pathway dynamics.

1. Selective GHS-R1a Engagement

Ipamorelin binds the growth-hormone secretagogue receptor (GHS-R1a, the ghrelin receptor), a Gq-coupled class A GPCR expressed on anterior-pituitary somatotrophs and selected peripheral tissues. Receptor engagement activates phospholipase-C, generates inositol-1,4,5-trisphosphate, and mobilizes intracellular calcium in laboratory research models.

2. Ghrelin-Receptor Signaling Research

Through GHS-R1a engagement, Ipamorelin is investigated as a probe for ghrelin-receptor-coupled signaling, including PLC/IP3/Ca2+ mobilization, MAPK pathway activation, and downstream transcriptional research in somatotroph cellular models.

3. Selectivity Profile in Receptor Research

Receptor-binding studies have characterized Ipamorelin as engaging GHS-R1a with minimal activity at adjacent endocrine receptor pathways. In laboratory research models, this selectivity is associated with absence of appreciable ACTH, cortisol, prolactin, or aldosterone receptor signaling, distinguishing it from earlier non-selective GHS research peptides.

4. Somatotropic-Axis Research Models

Ipamorelin is investigated alongside GHRH-receptor agonists (e.g., Sermorelin, CJC-1295, Tesamorelin) to study receptor-coupled signaling interactions between the GHS-R1a and GHRH-R pathways in controlled laboratory research.

Research Applications

Conclusion

Ipamorelin represents a structurally defined pentapeptide research compound that selectively engages the GHS-R1a (ghrelin) receptor. By providing high receptor selectivity within the somatotropic-axis research framework, it serves as a useful tool compound for examining ghrelin-receptor signaling research, selective GPCR pharmacology, and downstream growth-hormone-pathway dynamics in controlled laboratory models.

Research Use Disclaimer

This product is intended for research and laboratory use only. It is designed exclusively for in vitro research purposes. All information provided is for educational and research reference only. This product is not intended for human or animal use. It is not a drug, food, or cosmetic and must not be marketed, labeled, or used as such. Use and handling are restricted to trained and qualified professionals.